Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
Background - Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. - Objective - The objective of this paper is to present efficacy and safety results...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2026
|
| In: |
The journal of prevention of Alzheimer's disease
Year: 2026, Volume: 13, Issue: 4, Pages: 1-11 |
| ISSN: | 2426-0266 |
| DOI: | 10.1016/j.tjpad.2026.100507 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.tjpad.2026.100507 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2274580726000312 |
| Author Notes: | Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich |
Search Result 1